The Many Faces of Diabetes LIVE: Primary Prevention in Primary Care – SGLT2is in T2D

To understand through guidance where SGLT2 inhibitors fit in the overall treatment of T2D in primary care. To become familiar with the large cardiovascular outcome trials (CVOTs) in T2D and the cardiorenal and metabolic benefits of SGLT2 inhibitors. To understand which patients would benefit the most from an SGLT2 inhibitor and how they can be used during the GLP1-RA shortage.